AORT ARTIVION, INC.companySEC Filings & Insider Trading Activity 2026
Latest ARTIVION, INC. (AORT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 18, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on February 12, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ARTIVION, INC. (AORT) (SEC CIK 784199), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Manufacturer and distributor of medical devices and implantable human tissues for cardiac and vascular surgery, focusing on aortic disease treatment
- • New product launch: Arcevo™ LSA Hybrid Stent Graft System introduced in EMEA and APAC in 2025, with US PMA trial ongoing, plus PerClot® hemostatic powder manufacturing started Q2 2023
Risk Factors
- • Regulatory risk: Italian medical device overpayment repayment exposure $2.3M for 2019–2025 period under Ministerial Decree, potential further government assessment
- • Geopolitical risk: NEXUS products solely made in Israel amid Middle East conflicts, risking supply disruption from war, sanctions, or export controls
Management Discussion & Analysis
- • Revenue $441.3M in 2025, up 14% YoY from $388.5M in 2024; constant currency increase 13%
- • Gross margin 64% in 2025, flat YoY despite 14% gross margin dollar growth to $284.2M
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Capital expenditures $11.5M for nine months ended Sep 30, 2025 vs $9.8M YoY
- • Capex focused on manufacturing equipment, software, computer equipment, and leasehold improvements
Risk Factors
- • New risk: Italian medical device payback reduced by 75% after judicial challenges, finalized 2025 payment ~€0.1M reflecting regulatory/tax risk update
- • Updated regulatory risk: FDA Mtb tissue processing guidance withdrawn May 2025, public comments filed, potential to reduce available safe implantable tissue supply
Annual Reports Archive10-K
AI-powered analysis of ARTIVION, INC. (AORT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ARTIVION, INC. (AORT) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $313.8M | $354.0M | $388.5M | $441.3M |
| Gross Profit | $202.5M | $229.2M | $248.8M | $284.2M |
| Operating Income | — | $5.7M | $38.9M | $33.7M |
| Net Income | — | -$30.7M | -$13.4M | $9.8M |
| Gross Margin | 64.5% | 64.7% | 64.0% | 64.4% |
| Op. Margin | — | 1.6% | 10.0% | 7.6% |
| Net Margin | — | -8.7% | -3.4% | 2.2% |
| Balance Sheet | ||||
| Total Assets | — | $792.4M | $789.1M | $884.8M |
| Equity | — | $281.8M | $276.2M | $448.2M |
| ROE | — | -10.9% | -4.8% | 2.2% |
Source: XBRL financial data from ARTIVION, INC. (AORT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Feb 18, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 12, 2026 | — | — | |
10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 8, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 23, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 4, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 22, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 30, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 30, 2021 | Mar 31, 2021 | — | |
10-K | Feb 23, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — | |
10-Q | Jul 31, 2020 | Jun 30, 2020 | — | |
10-Q | May 1, 2020 | Mar 31, 2020 | — |
Frequently Asked Questions
What are the latest AORT SEC filings in 2026?
ARTIVION, INC. (AORT) has filed a 10-K annual report on February 18, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on February 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did AORT file its most recent 10-K annual report?
ARTIVION, INC. (AORT) filed its most recent 10-K annual report on February 18, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view AORT 10-Q quarterly reports?
ARTIVION, INC. (AORT)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every AORT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has AORT filed recently?
ARTIVION, INC. (AORT)'s most recent 8-K was filed on February 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find AORT insider trading activity (Form 4)?
SignalX aggregates every AORT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does AORT file with the SEC?
ARTIVION, INC. (AORT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AORT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARTIVION, INC. (AORT).
What is AORT's SEC CIK number?
ARTIVION, INC. (AORT)'s SEC CIK (Central Index Key) number is 784199. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 784199 to look up all AORT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find AORT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ARTIVION, INC. (AORT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ARTIVION, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 38+ filings.